RxDoctor Payments Data

James Tauras, MD

Internal Medicine · Bronx, NYNPI 1366683336

Payments from drug & device makers

$382,340in general payments, 2019–2025

Across 110 payments — averaging $3475.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$195K
  • Alnylam Pharmaceuticals Inc.$100K
  • Pfizer$65K
  • Eidos Therapeutics, Inc.$17K
  • Ortho-clinical Diagnostics, Inc.$4K
  • Actelion Pharmaceuticals US, Inc.$163
  • plus $357 from 4 others

What the payments were for

  • Consulting fees$11,12533%
  • Speaking & faculty fees$7,90024%
  • Travel & lodging$11,85436%
  • Food & beverage$2,3277%
  • Education$1420%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$382,340 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$60,849
Medicare patients
287
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis36$777,342
EntrestoSacubitril/Valsartan140$103,739
JardianceEmpagliflozin53$51,678
EliquisApixaban33$29,676
Eplerenone21$1,057
Metoprolol Succinate63$890
Furosemide60$287
Atorvastatin Calcium45$286
Carvedilol43$243
Spironolactone28$127
Torsemide16$108
ClopidogrelClopidogrel Bisulfate12$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$65,440$807,01869 claims
NovartisEntresto$195,314$103,739140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →